Research programme: adenosine A2B receptor antagonists - Allergan

Drug Profile

Research programme: adenosine A2B receptor antagonists - Allergan

Alternative Names: ATL-202; ATL-264; ATL-618; ATL-801; ATL-901; ATL-906; ATL-907

Latest Information Update: 15 Jul 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Adenosine Therapeutics LLC
  • Developer Allergan; Clinical Data
  • Class
  • Mechanism of Action Adenosine A2B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Asthma; Non-alcoholic fatty liver disease; Type 2 diabetes mellitus
  • Discontinued Chronic obstructive pulmonary disease; Ocular inflammation; Retinal disorders

Most Recent Events

  • 01 Jul 2014 Forest Laboratories has been acquired by Actavis Inc
  • 23 Dec 2010 Preclinical development is ongoing in Asthma and Type-2 diabetes mellitus in US
  • 03 Nov 2009 Preclinical trials in Non-alcoholic fatty liver disease in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top